DiaMedica Therapeutics reported net income of -$10.15M for the quarter ended Jun 2026. This income statement covers 35 quarters of results from Dec 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 19.04M | 20.77M | 26.44M | 26.44M | 26.44M | 26.44M | 26.46M | 27.31M | 37.95M | 37.96M | 37.96M | 42.69M | 42.77M | 42.82M | 42.86M | 43.07M | 52.08M | 53.74M | 53.88M | 53.93M | |||||||||||||||
| Revenue & cost | |||||||||||||||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 2.33M | 1.87M | 1.97M | 1.96M | 1.64M | 2.27M | 3.62M | 2.54M | 3.27M | 3.68M | 3.68M | 3.93M | 4.98M | 6.47M | 5.66M | 5.82M | 6.44M | 6.70M | 7.99M | 8.15M | |||||||||||||||
| Selling, General & AdministrativeSG&A | 1.08M | 1.38M | 1.56M | 1.41M | 1.49M | 1.70M | 1.90M | 2.20M | 1.89M | 2.17M | 2.06M | 1.71M | 1.90M | 1.95M | 2.49M | 2.19M | 2.60M | 2.51M | 2.50M | 2.35M | |||||||||||||||
| Operating ExpensesOpex | 3.42M | 3.25M | 3.54M | 3.36M | 3.13M | 3.97M | 5.52M | 4.74M | 5.16M | 5.85M | 5.74M | 5.64M | 6.88M | 8.42M | 8.14M | 8.01M | 9.03M | 9.21M | 10.48M | 10.50M | |||||||||||||||
| Operating IncomeOp. Inc | -3.42M | -3.25M | -3.54M | -3.36M | -3.13M | -3.97M | -5.52M | -4.74M | -5.16M | -5.85M | -5.74M | -5.64M | -6.88M | -8.42M | -8.14M | -8.01M | -9.03M | -9.21M | -10.48M | -10.50M | |||||||||||||||
| EBIT | -3.42M | -3.25M | -3.54M | -3.36M | -3.13M | -3.97M | -5.52M | -4.74M | -5.16M | -5.85M | -5.74M | -5.64M | -6.88M | -8.42M | -8.14M | -8.01M | -9.03M | -9.21M | -10.48M | -10.50M | |||||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.02M | 0.00M | 0.02M | ||||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | -0.00M | -0.05M | -0.06M | -0.06M | 0.01M | 0.09M | 0.04M | -0.03M | -0.06M | 2.00M | -0.04M | -0.01M | 0.62M | 0.54M | -0.02M | -0.02M | 0.44M | 0.47M | -0.08M | -0.01M | |||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.03M | 0.01M | 0.04M | 0.01M | 0.08M | 0.23M | 0.26M | 0.27M | 0.69M | 0.71M | 0.60M | 0.00M | -0.00M | 2.29M | 0.44M | 0.31M | -0.02M | 1.68M | 0.45M | 0.37M | |||||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.03M | 0.01M | 0.04M | 0.01M | 0.08M | 0.23M | 0.26M | 0.27M | 0.69M | 0.71M | 0.53M | 0.62M | 0.53M | 0.31M | 0.42M | 0.48M | |||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||||
| EBT | -3.44M | -3.24M | -3.50M | -3.35M | -3.05M | -3.74M | -5.26M | -4.47M | -4.46M | -5.14M | -5.14M | -5.11M | -6.27M | -7.93M | -7.70M | -7.69M | -8.61M | -9.11M | -10.04M | -10.13M | |||||||||||||||
| Tax ProvisionsTaxes | 0.01M | 0.02M | 0.01M | 0.01M | 0.01M | 0.04M | 0.01M | 0.01M | 0.01M | 0.02M | 0.01M | 0.01M | 0.01M | -3.68M | 0.01M | 0.01M | 0.01M | -4.93M | 0.01M | 0.01M | |||||||||||||||
| Profit After TaxPAT | -3.45M | -3.29M | -3.51M | -3.36M | -3.06M | -3.66M | -5.27M | -4.48M | -4.54M | -5.11M | -5.15M | -5.12M | -6.27M | -7.90M | -7.71M | -7.72M | -8.62M | -8.77M | -10.04M | -10.15M | |||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -3.45M | -3.26M | -3.51M | -3.36M | -3.06M | -3.79M | -5.27M | -4.48M | -4.47M | -5.16M | -5.15M | -5.12M | -6.27M | -4.25M | -7.71M | -7.70M | -8.62M | -4.18M | -10.04M | -10.14M | |||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -3.45M | -3.26M | -3.51M | -3.36M | -3.06M | -3.79M | -5.27M | -4.48M | -4.47M | -5.16M | -5.15M | -5.12M | -6.27M | -4.25M | -7.71M | -7.70M | -8.62M | -4.18M | -10.04M | -10.14M | |||||||||||||||
| Income towards Parent CompanyParent Net Inc | -3.45M | -3.26M | -3.51M | -3.36M | -3.06M | -3.79M | -5.27M | -4.48M | -4.47M | -5.16M | -5.15M | -5.12M | -6.27M | -4.25M | -7.71M | -7.70M | -8.62M | -4.18M | -10.04M | -10.14M | |||||||||||||||
| Net Income towards Common StockholdersNet Income | -3.45M | -3.26M | -3.51M | -3.36M | -3.06M | -3.79M | -5.27M | -4.48M | -4.47M | -5.16M | -5.15M | -5.12M | -6.27M | -4.25M | -7.71M | -7.70M | -8.62M | -4.18M | -10.04M | -10.14M | |||||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||||
| EPS (Basic) | -0.18 | -0.16 | -0.13 | -0.13 | -0.12 | -0.14 | -0.20 | -0.16 | -0.12 | -0.16 | -0.14 | -0.13 | -0.15 | -0.11 | -0.18 | -0.18 | -0.17 | -0.09 | -0.19 | -0.19 | |||||||||||||||
| Shares Outstanding | 19.04M | 20.77M | 26.44M | 26.44M | 26.44M | 26.44M | 26.45M | 27.31M | 37.95M | 32.57M | 37.96M | 38.07M | 42.75M | 40.40M | 42.84M | 42.96M | 49.63M | 46.98M | 53.79M | 53.89M | |||||||||||||||
| EBITDA | -3.42M | -3.25M | -3.54M | -3.36M | -3.13M | -3.97M | -5.52M | -4.74M | -5.16M | -5.85M | -5.74M | -5.64M | -6.88M | -8.42M | -8.14M | -8.01M | -9.03M | -9.21M | -10.48M | -10.50M | |||||||||||||||
| Interest ExpensesInt Expense | 0.02M | 0.00M | 0.02M | ||||||||||||||||||||||||||||||||
| Tax Rate | -0.20 | -0.71 | -0.20 | -0.21 | -0.23 | -1.10 | -0.13 | -0.16 | -0.16 | -0.43 | -0.14 | -0.14 | -0.11 | 46.45 | -0.08 | -0.08 | -0.07 | 54.10 | -0.07 | -0.07 |